Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Bioverativ

- PMLiVE

EC approves Janssen rare blood disorder drug

Sylvant available to treat multicentric Castleman's disease

- PMLiVE

Bayer’s CEO Dekkers to step down

And Sanofi CEO to move to US

- PMLiVE

Sanofi plans OTC version of Lilly’s Cialis

Deal could see erectile dysfunction drug become available without a prescription once its patents expire

National Institute for Health and Care Excellence NICE logo

NICE backs reimbursement of Sanofi’s MS drug Lemtrada

Final guidance opens doors for use on NHS in England and Wales

Shire Basingstoke

Shire boosts rare disease portfolio with $260m Lumena deal

Acquisition of US company will bring two mid-stage candidates for rare liver diseases

Biomarin

EC approves Biomarin rare genetic disorder drug

Vimizim now available to treat Morquio A syndrome

Sanofi reception

Sanofi won’t take part in mega-deal trend

CEO says French firm will stick to bolt-on acquisitions

Sanofi reception

Sanofi launches bursary scheme in UK

Funding to support initiatives that promote patient empowerment and education

- PMLiVE

FDA approves Janssen drug for rare Castleman’s disease

Sylvant approved to treat lymphoma-like condition

- PMLiVE

BioAlliance and Topotarget merge to focus on rare cancers

French and Danish firms combine to develop orphan oncology drugs

- PMLiVE

Sanofi takes to Twitter to support Spanish pharmacy portal

Says new account on the social network will help support community pharmacists

- PMLiVE

EU and Australian regulators collaborate on rare diseases

EMA and Therapeutic Goods Administration to share reports for orphan drugs

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links